calcium polystyrene sulfonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4871	37286-92-3

Description:

Molecule

Description

Synonyms:

calcium polystyrene sulfonate
calcium polystyrene sulphonate
calcium polystyrenesulfonate
kalimate

Molecular weight:
Formula: (C16H14CaO6S2)n
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
45	g	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	127.42	32.95	44	988	50821	56240214
Renal impairment	65.21	32.95	31	1001	80682	56210353
Cardiac failure	38.72	32.95	22	1010	82071	56208964

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	146.82	29.06	72	1748	64279	31631245
Crystal deposit intestine	72.07	29.06	11	1809	90	31695434
Renal impairment	46.72	29.06	39	1781	86310	31609214

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	257.38	27.38	114	2979	106477	70818874
Renal impairment	100.92	27.38	68	3025	143869	70781482
Crystal deposit intestine	73.78	27.38	12	3081	205	70925146
Shunt stenosis	57.62	27.38	13	3080	1299	70924052
Cardiac failure	54.28	27.38	47	3046	143494	70781857
Hepatic function abnormal	44.85	27.38	31	3062	67965	70857386
Anaemia	40.59	27.38	67	3026	403356	70521995
Chronic kidney disease	38.31	27.38	27	3066	61030	70864321
Interstitial lung disease	35.00	27.38	32	3061	104653	70820698
Shunt occlusion	30.99	27.38	8	3085	1407	70923944
Acute kidney injury	30.40	27.38	65	3028	474559	70450792

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
MeSH PA	D002411	Cation Exchange Resins
MeSH PA	D002614	Chelating Agents
MeSH PA	D007475	Ion Exchange Resins
MeSH PA	D064449	Sequestering Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
HUI2S00793	UNII
D03270	KEGG_DRUG
C0108139	UMLSCUI
CHEBI:53277	CHEBI
CHEMBL2109033	ChEMBL_ID
169893	PUBCHEM_CID
C003321	MESH_SUPPLEMENTAL_RECORD_UI
DB01344	DRUGBANK_ID
1546437	RXNORM
003509	NDDF
006664	NDDF
1002242008	SNOMEDCT_US
395788004	SNOMEDCT_US
710808009	SNOMEDCT_US
C0137904	UMLSCUI
CHEMBL1201484	ChEMBL_ID
8324	INN_ID
28210-41-5	SECONDARY_CAS_RN
75905	PUBCHEM_CID
ZSL2FB6GXN	UNII

Pharmaceutical products:

None